Scholarlink

Abstract <p>A new series of 1,3,4-oxadiazole–quinazolinone hybrids <b>9a</b>–<b>9j</b> have been synthesized, and their chemical structures were characterized by <sup>1</sup>H and <sup>13</sup>C NMR and mass spectral data. All compounds were preliminarily evaluated for their anticancer activity against four human cancer cell lines such as MCF-7 (breast cancer), A549 (lung cancer), SiHa (cervical cancer), and Colo-205 (colon cancer) in comparison with the clinically used anticancer drug etoposide as positive control. Among the tested compounds, <b>9e</b>, <b>9g</b>, and <b>9j</b> displayed more promising activity than etoposide. These compounds were also examined for their antibacterial and antifungal activities, and they exhibited potent activity. Molecular docking studies revealed that all ligands displayed strong binding interactions with FGFR1 and InhA targets, indicating potential efficacy in modulating these biological targets.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Design and Synthesis of 1,3,4-Oxadiazole–Quinazolinone Hybrids, Evaluation of Their Anticancer and Antimicrobial Activities, and Docking Studies

  • 期刊论文

  • 发表日期：

    2025年1月1日

查看全文
  • N. S. Suryanarayana,
  • Ch. Sridhar,
  • G. Hima Bindu

摘要

Abstract

A new series of 1,3,4-oxadiazole–quinazolinone hybrids 9a–9j have been synthesized, and their chemical structures were characterized by 1H and 13C NMR and mass spectral data. All compounds were preliminarily evaluated for their anticancer activity against four human cancer cell lines such as MCF-7 (breast cancer), A549 (lung cancer), SiHa (cervical cancer), and Colo-205 (colon cancer) in comparison with the clinically used anticancer drug etoposide as positive control. Among the tested compounds, 9e, 9g, and 9j displayed more promising activity than etoposide. These compounds were also examined for their antibacterial and antifungal activities, and they exhibited potent activity. Molecular docking studies revealed that all ligands displayed strong binding interactions with FGFR1 and InhA targets, indicating potential efficacy in modulating these biological targets.